Identification of genomic drivers for the therapeutic response of Cabozantinib in patients with metastatic renal cell carcinoma

Angelika Borkowetz,Ulrich Sommer,Gustavo Baretton,Carsten Gruellich,Björn Thorben Bürk,Holger H. H. Erb,Christian Thomas,MORECAB Consortium

DOI: https://doi.org/10.1007/s00345-024-04783-y

2024-02-23

World Journal of Urology

Abstract:Cabozantinib (CAB) as monotherapy or in combination with immune checkpoint inhibitors is used for systemic treatment of metastatic renal cell carcinoma (mRCC). However, little is known about predictors of treatment response to CAB. For this reason, known genomic drivers were examined to identify potential predictors of treatment response with CAB.

urology & nephrology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to identify the genomic drivers in patients with metastatic renal cell carcinoma (mRCC) receiving cabozantinib (CAB) treatment in order to predict treatment response. Specifically, the researchers hope to find potential biomarkers that can predict patients' response to cabozantinib treatment by analyzing known genomic drivers.

### Research Background
- **Cabozantinib**: Cabozantinib is a multi - target tyrosine kinase inhibitor (TKI) used to treat metastatic renal cell carcinoma. It can inhibit the formation of tumor neovascularization by suppressing vascular endothelial growth factor receptor (VEGF), RET during rearrangement, mesenchymal - epithelial transition factor (MET) and AXL pathways.
- **Treatment Response Prediction**: Although cabozantinib has shown good efficacy in clinical practice, currently, little is known about the predictive markers of its treatment response. Therefore, identifying genomic drivers that can predict treatment response is of great significance for optimizing treatment regimens.

### Research Objectives
- **Primary Objective**: To identify genomic drivers that can predict cabozantinib treatment response by analyzing genomic variations.
- **Specific Objectives**:
- Analyze the genomic variations in mRCC patients receiving cabozantinib monotherapy or combined with immune checkpoint inhibitors.
- Evaluate the relationship between these genomic variations and time to treatment failure (TFFS).

### Research Methods
- **Patient Selection**: Twenty mRCC patients receiving cabozantinib monotherapy were included.
- **Sample Processing**: DNA was extracted from archived primary tumor or metastatic tissues and subjected to targeted DNA sequencing.
- **Data Analysis**: Varsome software was used for variation assessment, the variation frequencies of different genes were counted, and the relationship between these variations and treatment response was analyzed.

### Main Findings
- **Common Gene Variations**: The most common pathogenic or likely pathogenic gene variations include PBRM1, SETD2, VHL and CHEK2.
- **Treatment Response**: Patients with SETD2 gene variation had a longer treatment response to cabozantinib (median TFFS not reached vs. 8.4 months without SETD2 variation, p = 0.024). However, patients with BRCA2 gene variation showed a shorter TFFS (0.99 months vs. 11 months without BRCA2 variation, p < 0.001).

### Conclusions
- **Genomic Variations and Treatment Response**: Pathogenic gene variations may indicate the treatment response of systemic therapy in mRCC. In particular, patients with SETD2 gene variation have a longer treatment response to cabozantinib.
- **Clinical Significance**: These findings are helpful for optimizing the individualized treatment strategies for mRCC patients and guiding treatment selection through genomic testing.

### Future Directions
- **Further Verification**: These findings need to be further verified in larger patient cohorts to determine their application value in clinical practice.
- **Mechanism Research**: Further explore how SETD2 and other gene variations affect the cabozantinib treatment response, so as to provide a theoretical basis for the development of new treatment strategies.